Shin Nippon Biomedical Laboratories, Ltd. (“SNBL”) is a Japanese publicly traded contract research organization. SNBL CPC is a clinical pharmacology facility located in the University of Maryland BioPark in Baltimore, Maryland, USA. The state of the art facility and equipment is bolstered by a vibrant research community. SNBL CPC specializes in complex Phase I-II trials, including TQT/Phase 1 QT de-risking, first-In-human (FIH), Japanese Bridging, and Phase II Proof of Concept (POC) studies. Proximity and the agreements that SNBL CPC has developed with the University of Maryland, Baltimore and Johns Hopkins University makes this facility best of its kind.
SNBL was looking to consolidate international operations but was a strong believer in the growth potential of SNBL CPC.
SC&H worked with Shin Nippon and SNBL CPC management to prepare the company for sale, defining key differentiators of the business and how they would be appealing to potential buyer groups, developing marketing materials, and a full financial model in US GAAP with contracted and projected future revenues.
SC&H designed a marketing process to initiate competitive tension within the CRO buying community. Pharmaron, a rapidly growing R&D service provider for the life sciences industry headquartered in China, quickly emerged as a great strategic fit. SNBL CPC naturally complements Pharmaron’s existing drug R&D services, further consolidating its clinical development capabilities, through synergistic integration with other recently acquired capabilities. This transaction involved a majority recapitalization of SNBL CPC by Pharmaron, where SNBL retained a minority equity position, reflecting the selling parent company’s belief in the long term growth potential of the business.